Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5885
    -0.0021 (-0.35%)
     
  • NZD/EUR

    0.5525
    -0.0020 (-0.36%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    82.35
    -0.38 (-0.46%)
     
  • GOLD

    2,397.30
    -0.70 (-0.03%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,833.35
    -43.70 (-0.55%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,724.43
    -112.97 (-0.63%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    90.9490
    -0.3050 (-0.33%)
     

How Much Upside Do Analysts See in Baxter Stock?

How Much Upside Do Analysts See in Baxter Stock?

Baxter International (BAX) provides a broad portfolio of essential healthcare products. Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating. Six have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.3 with a target price of $78.33, implying an upside potential of 4.1% over the stock’s closing price of $75.28 on June 5.